Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Li, Chenguang ^a,b,c   Fang, Rong ^a   Sun, Yihua ^b,c   Han, Xiangkun ^a   Li, Fei ^a   Gao, Bin ^a   Iafrate, A John ^d   Liu, Xin Yuan ^a   Pao, William ^e   Chen, Haiquan ^b,c   Ji, Hongbin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CD74 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ADULT; AGE; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; B RAF GENE; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; EML4 ALK GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; ROS1 GENE;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SMOKING;

EID: 82355161909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028204     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
3. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, et al. (2008) Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 5: e185.
4. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, et al. (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24: 2245-2251.
5. China. MohotPsRo (2010) Health Statistics of China 2010.
6. Subramanian J, Govindan R, (2007) Lung cancer in never smokers: a review. J Clin Oncol 25: 561-570.
7. Henschke CI, Yip R, Miettinen OS, (2006) Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 296: 180-184.
8. Sun Y, Ren Y, Fang Z, Li C, Fang R, et al. (2010) Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616-4620.
9. Charest A, Lane K, McMahon K, Park J, Preisinger E, et al. (2003) Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37: 58-71.
10. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
11. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, et al. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149.
12. Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, et al. (2011) A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer.
13. Sun YH, Fang R, Gao B, Han XK, Zhang JH, et al. (2010) Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin 31: 647-648.
14. Weir BA, Woo MS, Getz G, Perner S, Ding L, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
15. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
16. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
17. Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, et al. (2010) Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol 5: 1949-1952.
18. Cappuzzo F, Bemis L, Varella-Garcia M, (2006) HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354: 2619-2621.
19. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, et al. (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28: 3965-3972.
20. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, et al. (2010) Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 3076-3083.